A total of 18 recommendations were tracked for Emcure Pharma IPO. Out of 18 , 15 financial institutes/analysts have given rating for Subscribe, 3 for May Apply (50-50), 0 for Avoid and 0 hasn't given any rating. In terms of percentage 83.33% institutes has rated Emcure Pharma IPO for subscribe.
